Tetsuo Aida
Daiichi Sankyo
AntigenMolecular biologyAntibodyChemistryImmunologyAllergyPrimary and secondary antibodiesT cellBenzylpenicillinHumoral immunityKeyhole limpet hemocyaninGuinea pigPeptideTrastuzumabImmunopathologyToxicityStrain (chemistry)MedicineBiologyImmune systemPharmacology
14Publications
6H-index
239Citations
Publications 14
Newest
#1Daisuke Okajima (Daiichi Sankyo)H-Index: 4
#2Satoru Yasuda (Daiichi Sankyo)H-Index: 3
Last. Reiko Kamei (Daiichi Sankyo)H-Index: 1
view all 0 authors...
Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody-drug conjugate (ADC), Datopotamab deruxtecan (Dato-DXd, DS-1062a), with a potent DNA topoisomerase I inhibitor (DXd), and evaluated its antitumor activity and safety profiles in preclinical models. The pharmacological activity and mechanism of action of Dato-DXd were investigated in several human cancer cell lines and xenog...
Source
#1Kazuyoshi Kumagai (Daiichi Sankyo)H-Index: 7
#2Tetsuo Aida (Daiichi Sankyo)H-Index: 6
Last. Kazuhiko Mori (Daiichi Sankyo)H-Index: 9
view all 6 authors...
Trastuzumab deruxtecan (T-DXd: DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) Ab-drug conjugated with deruxtecan (DXd), a derivative of exatecan. The objective of this study was to characterize T-DXd-induced lung toxicity in cynomolgus monkeys. Trastuzumab deruxtecan was injected i.v. into monkeys once every 3 weeks for 6 weeks (10, 30, and 78.8 mg/kg) or for 3 months (3, 10, and 30 mg/kg). To evaluate the involvement of DXd alone in T-DXd-induced toxicity, DXd monohydrate ...
2 CitationsSource
#1Tomohiro Shirayanagi (Chiba University)H-Index: 1
#2Shigeki Aoki (Chiba University)H-Index: 7
Last. Kousei Ito (Chiba University)H-Index: 29
view all 9 authors...
The interaction of human leukocyte antigen (HLA) with specific drugs is associated with delayed-type hypersensitivity reactions, which cause severe cutaneous toxicity. Such interactions induce structural alterations in HLA complexes via several different mechanisms such as the hapten theory, p-i concept, and altered peptide repertoire model, leading to the activation of cytotoxic T cells. To date, comprehensive detection of such structural alterations in preclinical studies has been difficult. H...
1 CitationsSource
#1Eri Hamamura-Yasuno (Daiichi Sankyo)H-Index: 1
#2Tetsuo Aida (Daiichi Sankyo)H-Index: 6
Last. Kazuhiko Mori (Daiichi Sankyo)H-Index: 9
view all 4 authors...
Injection site reaction (ISR) is a common side-effect associated with the use of peptide or protein pharmaceuticals. These types of pharmaceuticals-induced activation of antigen-presenting cells is assumed to be a key step in the pathogenesis of immune-mediated ISR. The present study was designed to evaluate the immunostimulatory properties of peptide or protein pharmaceuticals using human monocytic THP-1 cells. Here, THP-1 cells, with or without phorbol-12-myristate-13-acetate (PMA) pretreatmen...
1 CitationsSource
#1Daisuke Okajima (Daiichi Sankyo)H-Index: 4
#2Satoru Yasuda (Daiichi Sankyo)H-Index: 3
Last. Toshinori Agatsuma (Daiichi Sankyo)H-Index: 12
view all 16 authors...
e24206Background: DS-1062a is a trophoblast cell surface protein 2 (TROP2)-targeting antibody-drug conjugate (ADC) comprised of a humanized anti-TROP2 monoclonal antibody, enzymatically cleavable p...
5 CitationsSource
#1Lydia M. Kwast (UU: Utrecht University)H-Index: 5
#2Tetsuo Aida (Daiichi Sankyo)H-Index: 6
Last. Raymond Pieters (UU: Utrecht University)H-Index: 36
view all 8 authors...
Immune-mediated drug hypersensitivity reactions (IDHR) may result from immuno-sensitization to a drug-induced neo-antigen. They rarely occur in patients and are usually not predicted preclinically using standard toxicity studies. To assess the potential of a drug to induce T-cell sensitization, trinitrophenyl (TNP)-Ficoll was used here as a bystander antigen in animal experiments. TNP-Ficoll will only elicit TNP-specific IgG antibodies in the presence of non-cognate T-cell help. Therefore, the p...
1 CitationsSource
#1Yusuke Ogitani (Daiichi Sankyo)H-Index: 8
#2Tetsuo Aida (Daiichi Sankyo)H-Index: 6
Last. Toshinori Agatsuma (Daiichi Sankyo)H-Index: 12
view all 16 authors...
Purpose: An anti-HER2 antibody–drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclinical pharmacologic profile was assessed. Experimental Design:In vitro and in vivo pharmacologic activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-positive cell lines and patient-derived xenograft (PDX) models. The mechanism of action for the efficacy was also evaluated. Pharmacokinetics in cynomolgus monkeys an...
210 CitationsSource
#1Ryota Kawai (Daiichi Sankyo)H-Index: 4
#2Tetsuo Aida (Daiichi Sankyo)H-Index: 6
Last. Teruo Kawada (Kyoto University)H-Index: 64
view all 8 authors...
T-cell dependent antibody response (TDAR) incorporating both primary and secondary responses to keyhole limpet hemocyanin (KLH) in canine models have not yet been fully understood. To develop a practical dog TDAR model, we characterized primary and secondary antibody responses by intravenous or intramuscular immunization of KLH twice at intervals of 8 days during a 28-day course of study. Primary immunization with KLH by both routes induced a maximum IgM response on 6 to 8 days after the treatme...
6 CitationsSource
#1Ryota KawaiH-Index: 4
#2Shiho ItoH-Index: 1
Last. Teruo Kawada (Kyoto University)H-Index: 64
view all 9 authors...
To develop a rat T-cell-dependent antibody response (TDAR) model evaluating both primary and secondary antibody responses, keyhole limpet hemocyanin (KLH) was used to immunize rats twice during a 14-day course of study, a pattern closely linked to that of a short-term general toxicity study. Female rats of four representative strains (e.g., Sprague-Dawley, Wistar, Fischer, and Lewis) were immunized twice with intravenous administrations of KLH (300 µg/rat) on Days 5 and 9 during a 14-day treatme...
18 CitationsSource
#1Tetsuo AidaH-Index: 6
#2Ryota KawaiH-Index: 4
Last. Tadashi FurukawaH-Index: 8
view all 4 authors...